Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Gh. Toogeh"'
Autor:
Gh. Toogeh, A. H. Najafi M. Keyhani
Publikováno v:
Acta Medica Iranica, Vol 41, Iss 4, Pp 227-232 (2003)
Cytogenetics has now been well established as one of the most valuable prognostic factors in acute myeloid leukemia (AML). This is the first study to describe the cytogenetic findings in Iranian AML patients. During 1998 to 2001, 104 patients with ad
Externí odkaz:
https://doaj.org/article/ecd0ef02d1a44a2794a0061d61e8e63b
Autor:
Ehsan Arefian, M. Kohram, Fatemeh Kohram, H. Teimori Naghadeh, Behzad Poopak, Naser Amirizadeh, Parviz Fallah, Masoud Soleimani, S. M. A. Hosseini Rad, Gh. Toogeh
Publikováno v:
International Journal of Laboratory Hematology. 37:560-568
Summary Introduction Chronic myeloid leukemia (CML) is caused by reciprocal translocation in hematopoietic stem cells (HSCs). This translocation forms the BCR-ABL1 oncogene, which alters several signaling pathways that control malignancy. CML has thr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72eeb280c8a6cc207dd871e86ca7422b
https://doi.org/10.1111/ijlh.12351
https://doi.org/10.1111/ijlh.12351
Autor:
Azita Azarkeivan, Kamran Atarodi, Mohammad Vaezi, Seyed H. Ghaffari, Kamran Alimoghaddam, Reza Shirkoohi, Shirin Ferdowsi, Naser Amirizadeh, Gh. Toogeh, Mohammad Faranoush, H. Teimori Naghadeh, A. Ghavamzadeh
Publikováno v:
International journal of laboratory hematology. 37(5)
SUMMARY Introduction: The JAK2V617F mutation has emerged in recent years as a diagnostic as well as a treatment target in patients with polycy- themia vera (PV) and essential thrombocythemia (ET). The disease phenotype is also influenced by other fac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5815e13fa4b5a864bd24c2c3bce726d
https://pubmed.ncbi.nlm.nih.gov/26011312
https://pubmed.ncbi.nlm.nih.gov/26011312
Autor:
B. khoeiny, R. Fayazfar, Gh. Toogeh, Mohammad Faranoush, Mehran Karimi, Hassan Abolghasemi, K. Kamyar, B. Keikhaei Dehdezi, Majid Naderi, N B Mirbehbahani, Hamid Hoorfar, Peyman Eshghi, M. R. Baghaeipour, Fereidoun Mahboudi, R. Heshmat, Mohammadreza Managhchi, Minoo Ahmadinejad, B. Vaziri, Azim Mehrvar
Publikováno v:
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 22(2)
Introduction: This study compared the efficacy of Aryoseven with Novoseven to control bleeding episodes in patients with hemophilia A with inhibitors. Methods: Sixty-six patients were randomized into 2 groups, with 4 consecutive block randomization.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::215b6d61082844e0bd71e4e14744085d
https://pubmed.ncbi.nlm.nih.gov/25343955
https://pubmed.ncbi.nlm.nih.gov/25343955
Autor:
M. R. Baghaeipour, Hamid Hoorfar, Peyman Eshghi, Majid Naderi, Gh. Toogeh, Minoo Ahmadinejad, Mohammadreza Managhchi, Azim Mehrvar, N B Mirbehbahani, B. khoeiny, R. Heshmat, Mohammad Faranoush, B. Keikhaei Dehdezi, Mehran Karimi, Hassan Abolghasemi, K. Kamyar, R. Fayazfar
Publikováno v:
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 21(8)
In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 μg/kg, intravenously per week for 4 weeks, in a randomized fashion.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58fe1a88b08b6a84199908f16ebefc91
https://pubmed.ncbi.nlm.nih.gov/24651301
https://pubmed.ncbi.nlm.nih.gov/24651301
Autor:
Minoo Ahmadinejad, Hamid Hoorfar, Hassan Abolghassemi, B Mehrvar, Mohammad Baghaeipour, Behrooz Vaziri, R. Fayazfar, NB Mirbehbahhani, R. Heshmat, F Mahbodi, Mohammad Faranoush, K Kaymar, Peyman Eshghi, Babak Khoein, Mehran Karimi, Dehdezi B Keikhaei, Gh. Toogeh, Majid Naderi, Mohammadreza Managhchi
Publikováno v:
Blood. 124:4299-4299
Introduction: Concentrated factor VIII replacement therapy in severe hemophilia prevents disabling arthropathy, life-threatening bleeding, improves health related quality of life and increase life expectancy. Patients with neutralizing antibodies (in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8f4a4f6f59baed25a2227bb9e332092
https://doi.org/10.1182/blood.v124.21.4299.4299
https://doi.org/10.1182/blood.v124.21.4299.4299
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.